Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04432454 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
A Phase 2 study, sponsored by Sermonix Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT04432454 is a Phase 2 study that has completed, run by Sermonix Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT04432454, a Phase 2 study, has completed, sponsored by Sermonix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation.
Interventions
- DRUG Lasofoxifene and abemaciclib (VERZENIO (R)).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04432454
The ClinicalTrials.gov registry entry for NCT04432454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sermonix Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lasofoxifene and abemaciclib (VERZENIO (R)). is the first listed.
NCT04432454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04432454 about?
NCT04432454 is a clinical study titled "Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation". This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/...
What is the current status of trial NCT04432454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2020-09-29. Estimated completion is 2025-01-28.
What interventions are being tested in trial NCT04432454?
The interventions under investigation include: Lasofoxifene and abemaciclib (VERZENIO (R)). (DRUG).
Who is sponsoring clinical trial NCT04432454?
This trial is sponsored by Sermonix Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.